Nina’s role is to ensure that patients have faster access to the most promising new treatments, taxpayers get better value for money in drug expenditure and the route to funding is speeded up for responsibly priced, promising drugs. This includes responsibility for the Innovative Medicines Fund, the Cancer Drugs Fund, industry relations, patient access schemes (PAS), the Blueteq prior approval system, dose banding and budget impact tests.
Nina has worked in the NHS since 2001, starting at the National Institute for Health and Care Excellence (NICE). Nina developed and improved the process for technology appraisal and redesigning how NICE choose the topics it produces guidance on. Follow a year’s secondment in 2015 to the Office for Life Sciences as a Senior Policy Lead working on the Accelerated Access Review, Nina returned to NICE to set up, launch and subsequently head up Office for Market Access before moving to NHS England in 2016